Leerink Partners Maintains Outperform on Incyte, Lowers Price Target to $150

Benzinga · 1d ago
Leerink Partners analyst Andrew Berens maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $154 to $150.